Goldman Sachs Remains a Buy on Braveheart Bio, Inc. (BRVE)
TipRanks (Wed, 9-Sep 7:55 AM ET)
Analysts Offer Insights on NA Companies: IMAX (IMAX) and Braveheart Bio, Inc. (BRVE)
TipRanks (Wed, 9-Sep 7:10 AM ET)
Braveheart Bio, Inc. reports Q2 results
Seeking Alpha News (Tue, 8-Sep 4:04 PM ET)
Braveheart Bio Reports Second Quarter 2026 Financial Results and Provides Business Update
Globe Newswire (Tue, 8-Sep 4:03 PM ET)
The Market Barely Knows These 2 IPO Stocks — Goldman Sachs Says ‘Buy’
TipRanks (Tue, 8-Sep 6:01 AM ET)
Analysts Offer Insights on NA Companies: Braveheart Bio, Inc. (BRVE) and TeraWulf Inc (WULF)
TipRanks (Mon, 7-Sep 4:10 AM ET)
Braveheart Bio to Participate in Cantor Global Healthcare Conference
Globe Newswire (Tue, 1-Sep 4:30 PM ET)
Globe Newswire (Fri, 7-Aug 4:05 PM ET)
Braveheart Bio Inc is a clinical-stage biotechnology company focused on developing therapeutics to treat hypertrophic cardiomyopathy (HCM) and other cardiovascular diseases. Its flagship product candidate, BHB-1893, is an oral small-molecule cardiac myosin inhibitor being developed for the treatment of obstructive HCM (oHCM) and non-obstructive HCM (nHCM).
Braveheart Bio trades on the NASDAQ stock market under the symbol BRVE.
As of September 8, 2026, BRVE stock price climbed to $29.41 with 604,960 million shares trading.
BRVE has a market cap of $2.15 billion. This is considered a Mid Cap stock.
The top ETF exchange traded funds that BRVE belongs to (by Net Assets): FMED.
BRVE support price is $25.31 and resistance is $28.17 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that BRVE shares will trade within this expected range on the day.